HLB Co. Chairman Jin Yang-gon. [Courtesy of HLB] South Korean pharmaceutical HLB Co. is poised to venture into new therapeutic areas, including chimeric antigen receptor T cell, or CAR-T cell therapy, and a glioblastoma treatment, according to Chairman Jin Yang-gon.'HLB is ready to ramp up its drive for new drug pipelines using the lessons learned from Riboceranib's success,' Jin said in his interview with the Maeil Business Newspaper.Rivoceranib is a small-molecule, oral tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor 2 (VEGFR-2), a crucial pathway for tumor angiogenesis.

https://n.news.naver.com/mnews/article/009/0005184750?sid=104

#naver